Free Trial
NASDAQ:IOBT

IO Biotech Q2 2024 Earnings Report

IO Biotech logo
$1.49 -0.07 (-4.49%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 +0.01 (+0.67%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IO Biotech EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.35
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

IO Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IO Biotech Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

IO Biotech's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Friday, November 7, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

IO Biotech Earnings Headlines

This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
See More IO Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IO Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IO Biotech and other key companies, straight to your email.

About IO Biotech

IO Biotech (NASDAQ:IOBT) ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access.

IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.

View IO Biotech Profile

More Earnings Resources from MarketBeat